Peninsula doripenem starts Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Peninsula's intravenous carbapenem antibiotic doripenem enters Phase III studies for complicated intra-abdominal infections, the firm says March 30. Per FDA guidelines, the primary endpoint will be response at test of cure visit...
Peninsula's intravenous carbapenem antibiotic doripenem enters Phase III studies for complicated intra-abdominal infections, the firm says March 30. Per FDA guidelines, the primary endpoint will be response at test of cure visit.... |